Document Detail

Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer.
MedLine Citation:
PMID:  21607554     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To compare docetaxel-based doublet with single-agent docetaxel as second-line treatment in non-small-cell lung cancer (NSCLC).
METHODS: We systematically searched for randomized clinical trials that compared docetaxel-based doublet with single-agent docetaxel in patients with histologically proven non-small-cell lung cancer. The primary end point was overall survival (OS). Secondary end points were progression-free survival, overall response rate, 1-year survival rate, and grade 3 or 4 toxicity. Data were extracted from the studies by two independent reviewers. The meta-analysis was performed by Stata version 10.0 software (Stata Corporation, College Station, TX, USA).
RESULTS: Eight randomized clinical trials (totally 2,126 patients) were eligible. Meta-analysis showed that there was significant improvement in PFS (HR 0.81, 95% CI 0.69-0.96, P = 0.013) and overall response rate (OR 1.42, 95% CI 1.13-1.80, P = 0.03) in docetaxel-based doublet group, compared with docetaxel alone, though the pooled HR for overall survival (HR 0.93, 95% CI 0.80-1.07, P = 0.308) showed no significant difference between the two groups. However, there were more incidences of grade 3 or 4 neutropenia (OR 1.2, 95% CI 1.00-1.45, P = 0.05), thrombocytopenia (OR 4.53, 95% CI 1.75-11.75, P = 0.002), and diarrhea (OR 1.78, 95% CI 1.16-2.74, P = 0.008) in docetaxel-based doublet group. With regard to the risk of grade 3 or 4 anemia (OR 1.95, 95% CI 0.62-6.17, P = 0.25), fatigue (OR 1.09, 95% CI 0.75-1.59, P = 0.66), and nausea and vomiting (OR 1.75, 95% CI 0.78-3.91, P = 0.17), there was no significant difference between the two groups.
CONCLUSIONS: This was the first meta-analysis of docetaxel-based doublet versus single-agent docetaxel as second-line therapy in the treatment of non-small-cell lung cancer. The results indicated that docetaxel-based doublet therapy did not gain any benefit in survival but significantly improved PFS and better ORR versus single-agent docetaxel. However, more incidences of grade 3 or 4 neutropenia, thrombocytopenia, and diarrhea were observed in docetaxel-based doublet group.
Wei-Xiang Qi; Zan Shen; Yang Yao
Related Documents :
9275344 - A one-hand operation gun for transrectal prostate biopsy.
10796804 - Maximal androgen blockade for advanced prostate cancer.
23374154 - Survival rates in patients with diabetes on peritoneal dialysis in china.
23740894 - Randomized phase iii trial of concurrent chemoradiotherapy vs accelerated hyperfraction...
12560774 - Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look int...
18270974 - Can surgeons improve survival in stage iv melanoma?
Publication Detail:
Type:  Comparative Study; Journal Article; Meta-Analysis     Date:  2011-05-24
Journal Detail:
Title:  Cancer chemotherapy and pharmacology     Volume:  69     ISSN:  1432-0843     ISO Abbreviation:  Cancer Chemother. Pharmacol.     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2012-01-02     Completed Date:  2012-02-17     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  7806519     Medline TA:  Cancer Chemother Pharmacol     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  99-106     Citation Subset:  IM    
Department of Oncology, The Sixth People Hospital, Medical College of Shanghai Jiao Tong University, Shanghai 200233, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / administration & dosage,  adverse effects,  therapeutic use
Antineoplastic Combined Chemotherapy Protocols / adverse effects,  therapeutic use*
Carcinoma, Non-Small-Cell Lung / drug therapy*,  pathology
Disease-Free Survival
Lung Neoplasms / drug therapy*,  pathology
Randomized Controlled Trials as Topic
Survival Rate
Taxoids / administration & dosage,  adverse effects,  therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Antineoplastic Agents; 0/Taxoids; 15H5577CQD/docetaxel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
Next Document:  Modification of uptake and subcellular distribution of doxorubicin by N-acylhydrazone residues as vi...